相关实验视频
Updated: Jan 6, 2026
01:19
Mitral Valve Prolapse III: Nursing Management
Published on: June 19, 2025
252
儿童和青少年慢性偏头痛的认知行为疗法加上阿米林:随机临床试验
Scott W Powers1, Susmita M Kashikar-Zuck2, Janelle R Allen3
1Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio3Headache Center, Cincinnati Children's Hospital Medical Center4Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
JAMA
|December 26, 2013
概括
认知行为疗法 (CBT) 与阿米素结合,与头痛教育相比,显著减少了年轻人的慢性偏头痛日和残疾. 这种组合疗法为儿科慢性偏头痛提供了一种有效的,基于证据的治疗选择.
科学领域:
- 儿科神经学 儿科神经学
- 儿童和青少年精神病学 儿童和青少年精神病学
- 行为医学是一种行为医学.
背景情况:
- 儿童和青少年的慢性偏头痛缺乏安全,有效和持久的基于证据的干预措施.
- 目前的治疗方案往往无法提供持续的缓解或解决儿科慢性偏头痛的多面性质.
研究的目的:
- 为了比较认知行为疗法 (CBT) 加上阿米特利普提林与头痛教育加上阿米特利普提林在治疗年轻人的慢性偏头痛的疗效.
- 在12个月的时间内,评估这些联合干预措施对头痛频率和偏头痛相关残疾的影响.
主要方法:
- 一项随机临床试验,涉及135名患有慢性偏头痛的青少年 (10-17岁).
- 参与者接受了10次CBT或头痛教育,同时接受了阿米特林 (1 mg/kg/d).
- 主要结局包括头痛日和20周的儿科偏头痛残疾评估分数 (PedMIDAS),并对耐久性进行12个月的随访.
主要成果:
- 在20周后,CBT加上阿米西林组的头痛日 (4.7天差异,P=.002) 和PedMIDAS得分 (14.1分差异,P=.01) 显著减少.
- 20周后,66%的CBT组在头痛日减少了50%以上,而教育组的头痛日减少了36% (P<.001).
- 在12个月的长期随访中,证明了持续的益处,其中86%的CBT组经历了≥50%的头痛减轻,88%实现了轻度残疾.
结论:
- 认知行为疗法与阿米林相结合,比头痛教育加阿米林更有效地减少慢性偏头痛的年轻人头痛频率和残疾.
- 这些发现提供了强有力的证据,证明CBT的有效性和耐用性是儿童群体慢性偏头痛管理的关键组成部分.
相关概念视频
Mitral Valve Prolapse III: Nursing Management
252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines
917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence
759
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations
51.1K
Overview
51.1K
Healthcare Associated Infections II: Preventive Measures
3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K